Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chromadex Corp CS
(NQ:
CDXC
)
7.630
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7
Open
7.630
Bid (Size)
7.500 (3)
Ask (Size)
7.740 (21)
Prev. Close
7.630
Today's Range
7.630 - 7.630
52wk Range
1.320 - 7.850
Shares Outstanding
68,196,526
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
November 14, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
November 07, 2024
From
ChromaDex Corporation
Via
Business Wire
Performance
YTD
+433.57%
+433.57%
1 Month
+118.62%
+118.62%
3 Month
+131.91%
+131.91%
6 Month
+134.77%
+134.77%
1 Year
+426.21%
+426.21%
More News
Read More
Insights into ChromaDex's Upcoming Earnings
October 30, 2024
Via
Benzinga
CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024
August 07, 2024
Via
InvestorPlace
What You Missed On Wall Street This Past Friday
November 03, 2024
Via
Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
November 01, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
November 01, 2024
Via
Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
November 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 31, 2024
Via
Benzinga
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
October 31, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 28, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in the 17th Annual LD Micro Main Event
October 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
October 15, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
September 26, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
September 20, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
September 10, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
September 09, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
August 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
August 19, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
August 07, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 05, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 24, 2024
From
ChromaDex Corporation
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
